Martin Mattingly, a veteran executive at several life-science and pharmaceutical firms, is the new chief executive officer at Trimeris.
Mattingly’s most recent position was CEO at Ambryx Pharmaceuticals. He also has worked at CancerVax, Agouron Pharmaceuticals, Pfizer and Eli Lilly.
While at Agouron, Mattingly led the firm’s HIV division. He also worked with HIV products at Pfizer.
Julian Baker, a member of the Trimeris (Nasdaq: ) board, said Mattingly’s experience in HIV products was a key factor in his selection as CEO.
Trimeris’ only product, Fuzeon, treats HIV. The firm also recently decided to continue development of another potential HIV product, regaining all rights to it from the firm’s Fuzeon partner Roche.
“Martin’s hands-on experience in commercializing HIV products in crowded markets and in maximizing the value of these products as they mature is an ideal fit for Trimeris,” Baker said in a statement. “During his tenure at Agouron and Pfizer, Martin was actively involved in both the successful launch of Viracept … and its life-cycle management as numerous competitors entered the market.”
Mattingly also was named to the Trimeris board. He received a doctor of pharmacy degree at the University of Kentucky.
E. Lawrence Hill and Daniel Ratto, executives brought in to run Trimeris in a management shakeup last March, are leaving the company as of Jan. 2.
Dani Bolognesi, one of Trimeris’ co-founders, was asked to resign as CEO by the Trimeris board in March. Robert Bonzcek, the CFO, also was asked to step down.
